Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $28.82 and traded as low as $28.35. Pfizer shares last traded at $28.4050, with a volume of 35,276,356 shares traded.
Pfizer News Roundup
Investors following PFE have been watching these news items:
- Positive Sentiment: Pfizer’s agreement with Starna Therapeutics gives it rights outside Greater China to develop three in vivo CAR-T programs for autoimmune diseases. The deal expands Pfizer’s pipeline and could open a new avenue for growth beyond its existing products. Reuters article
- Neutral Sentiment: Pfizer reported updates on a Phase 3 study of berobenatide and a real-world study of its migraine drug Nurtec. The headlines provided no new efficacy or safety results, so the near-term investment impact is unclear. Berobenatide study article
- Positive Sentiment: Pfizer is scheduled to pay its 352nd consecutive quarterly dividend on Dec. 7, a long-running payout that may appeal to income-focused investors, though it is not a new increase. Dividend article
Analyst Upgrades and Downgrades
PFE has been the subject of several research reports. Weiss Ratings raised shares of Pfizer from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. FBN Securities set a $34.00 target price on Pfizer in a research note on Friday, November 6th. DZ Bank downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, November 6th. Argus set a $40.00 price target on Pfizer in a research note on Wednesday, November 4th. Finally, Royal Bank Of Canada upped their price objective on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a report on Wednesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $30.32.
Read Our Latest Report on Pfizer
Pfizer Stock Performance
The firm’s 50 day simple moving average is $28.83 and its 200 day simple moving average is $27.02. The firm has a market capitalization of $157.12 billion, a price-to-earnings ratio of 9.20, a PEG ratio of 1.84 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The firm’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is presently 245.71%.
Institutional Investors Weigh In On Pfizer
A number of large investors have recently made changes to their positions in PFE. BlackRock Inc. boosted its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. State Street Corp raised its holdings in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares during the period. Bank of America Corp DE purchased a new position in Pfizer in the 2nd quarter valued at approximately $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pfizer by 4.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock worth $870,668,000 after acquiring an additional 1,634,374 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Featured Stories
- Five stocks we like better than Pfizer
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
